The scrutiny continues of the Medicaid rebate for Mylan NV's Epipen, as the Senate Judiciary Committee seeks more than hearsay on communications between the company and the Centers for Medicare & Medicaid Services (CMS) on whether Epipen qualifies for the noninnovator, or generic, rebate.